STL Index for: Susan Poelman

Lebrikizumab is a new IL-13 targeting monoclonal antibody approved for moderate-to-severe atopic dermatitis in patients 12+ years. Learn about clinical trial efficacy, safety data, dosing, and how it compares to other AD biologics like dupilumab and tralokinumab.

Comprehensive review of methoxyflurane inhaled analgesia in dermatology, discussing efficacy, safety, and applications in outpatient procedures for effective pain management.